Skip to main content
. 2015 Apr 29;6:9. doi: 10.1186/s13293-015-0027-9

Table 2.

Impact of chronic androgen treatment and GDX on resting and action potentials

a Component Treatment Duration (weeks) Preparation Functional change Species Reference
Testosterone supplementation
RMP bTestosterone 4 Ventricular muscle ↔ Rat [84]
cDihydrotestosterone 13 Ventricular myocyte ↔ Mouse [39]
AP amplitude bTestosterone 4 Ventricular muscle ↔ Rat [84]
APD50 bTestosterone 4 Ventricular muscle ↔ Rat [84]
cDihydrotestosterone 13 Ventricular myocyte ↓ Mouse [39]
APD90/95 bTestosterone 4 Ventricular muscle ↑ Rat [84]
cDihydrotestosterone 13 Ventricular myocyte ↓ Mouse [39]
Gonadectomy (GDX)
RMP GDX 4 Ventricular muscle ↔ Rat [84]
11–15 Ventricular myocyte ↔ Mouse [39]
AP amplitude GDX 4 Ventricular muscle ↔ Rat [84]
APD50 GDX 4 Ventricular muscle ↑ Rat [84]
11–15 Ventricular myocyte ↑ Mouse [39]
APD90/95 GDX 4 Ventricular muscle ↔ Rat [84]
11–15 Ventricular myocyte ↑ Mouse [39]

aAll experiments used paced tissues and myocytes from male animals only. bTestosterone treatment with 5 mg/kg/day. cDihydrotestosterone treatment with a 7.5-mg pellet.